Study analysis · Journal of Alzheimer's Disease · 2024
Could a common vitamin-like supplement slow Alzheimer's? Two small human trials suggest yes, but the science is far from settled.
This review of studies on NAD+ supplements (NR and NMN) found some promising cognitive and biomarker improvements in a few human trials for NR, but no human tests for NMN -- so we can't say they work yet.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
Imagine you collected a bunch of reports from scientists who tested a new vitamin in mice and a couple of people. Some mice got better, and a few people showed improvements in memory tests. That’s a hint that the vitamin might help, but it’s not strong proof because we don’t know if the people taking it were compared to others who didn’t take it. So we can say ‘this vitamin might be linked to better memory,’ but we can’t say ‘this vitamin cures Alzheimer’s.’
What’s the bottom line?
This study looked at research on two special vitamins (NMN and NR) that might help people with Alzheimer's disease. They found some promising results in mice and a few human studies, but more research is needed.
How strong is this study?
Limited - based on abstract only, full methodology not available
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. The systematic review includes mainly preclinical animal studies and only two human clinical trials that are not explicitly described as randomized controlled trials. Without randomization and control groups, causation cannot be established.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the abstract, making it impossible to assess potential biases.
The abstract lacks any declarations regarding conflicts of interest, funding sources, or author affiliations. Further review of the full text is necessary to determine potential biases.
Key takeaways
- 01
They found 3 mouse studies and 4 mouse studies with one type, and 2 human studies with another type showed some improvements in thinking and brain health.
- 02
The human studies were small, so it's not yet proven to work for everyone.
Surprising findings
- NMN, a popular supplement, has zero human trials for Alzheimer's – only 3 mouse studies.Many people buy NMN based on preclinical hype, but this review highlights the complete lack of human evidence for Alzheimer's specifically.
- Despite only 2 human trials, the review concludes that results 'confirm the potential benefits' of NAD+ precursors.This wording may overstate the evidence – two small trials are not confirmatory. The conclusion seems more optimistic than the data warrant.
Practical takeaways
If you are considering NR or NMN supplements for Alzheimer's prevention or treatment, be aware that the human evidence is extremely limited (only 2 small NR trials, zero NMN human trials).
Full paper not available; methodology and details of these trials cannot be verified. Consult a doctor before taking any supplement.
low confidenceFocus on established lifestyle interventions (diet, exercise, social engagement) for brain health, as these have stronger evidence than NAD+ precursors.
This tip is not from the study but from general Alzheimer's prevention research.
low confidenceWhy this study matters
Only 2 Human Trials for NR, Zero for NMN
The review identified only two human clinical trials testing nicotinamide riboside (NR) in Alzheimer's patients, showing improvements in blood markers, brain scans, and cognition. For nicotinamide mononucleotide (NMN), no human trials exist – only 3 mouse studies.
The public often assumes supplements are backed by strong evidence. Here, the human data is extremely thin, especially for NMN which is widely marketed.
Mouse to Human Gap
4 preclinical NR studies and 3 preclinical NMN studies showed benefits in mice, but only NR has made it to human testing. The leap from rodent to human is huge, and many promising mouse treatments fail in people.
Highlights the danger of assuming animal results apply to humans – a key concept for science literacy.
Systematic Review, Not New Data
This is a systematic review following PRISMA guidelines, not a new experiment. It summarizes existing studies, which themselves are small and limited. Confidence in the findings is low due to lack of full-text access and no meta-analysis.
Helps audiences understand different levels of scientific evidence – a review is only as good as the studies it includes.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at research on two special vitamins (NMN and NR) that might help people with Alzheimer's disease. They found some promising results in mice and a few human studies, but more research is needed.
Research results
They found 3 mouse studies and 4 mouse studies with one type, and 2 human studies with another type showed some improvements in thinking and brain health.
What this means - more context
The human studies were small, so it's not yet proven to work for everyone.
To assess therapeutic value of NAD+ precursors (NMN and NR) for Alzheimer's disease using preclinical and clinical studies from last 5 years.
Systematic review of 3 NMN preclinical, 4 NR preclinical, and 2 NR human trials suggests potential cognitive and biomarker improvements with NAD+ precursors, but more clinical research needed.
Methods Used
Systematic review following PRISMA guidelines, searching two databases for studies published in last 5 years.
Main Finding
Potential benefits of NAD+ precursors (NR and NMN) for Alzheimer's disease, with 2 human trials showing improvements in biomarkers and cognition for NR, but no human trials for NMN.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No meta-analysis performed
- •Limited human trials (only 2) for NR, none for NMN
Surprising Findings
NMN, a popular supplement, has zero human trials for Alzheimer's – only 3 mouse studies.
Many people buy NMN based on preclinical hype, but this review highlights the complete lack of human evidence for Alzheimer's specifically.
Practical Takeaways
If you are considering NR or NMN supplements for Alzheimer's prevention or treatment, be aware that the human evidence is extremely limited (only 2 small NR trials, zero NMN human trials).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Human Systematic Review
Subject
Lower probability
on the GRADE evidence scale
Imagine you collected a bunch of reports from scientists who tested a new vitamin in mice and a couple of people. Some mice got better, and a few people showed improvements in memory tests. That’s a hint that the vitamin might help, but it’s not strong proof because we don’t know if the people taking it were compared to others who didn’t take it. So we can say ‘this vitamin might be linked to better memory,’ but we can’t say ‘this vitamin cures Alzheimer’s.’
Strengths
- Followed PRISMA guidelines for systematic review.
- Focused on a specific intervention (NAD+ precursors) and disease (Alzheimer's).
Weaknesses
- Full methodology not available - based on abstract only.
- Only searched two databases, potentially missing relevant studies.
- Included a mix of animal and human studies without separate analysis.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at research on two special vitamins (NMN and NR) that might help people with Alzheimer's disease. They found some promising results in mice and a few human studies, but more research is needed.
Research results
They found 3 mouse studies and 4 mouse studies with one type, and 2 human studies with another type showed some improvements in thinking and brain health.
What this means - more context
The human studies were small, so it's not yet proven to work for everyone.
To assess therapeutic value of NAD+ precursors (NMN and NR) for Alzheimer's disease using preclinical and clinical studies from last 5 years.
Systematic review of 3 NMN preclinical, 4 NR preclinical, and 2 NR human trials suggests potential cognitive and biomarker improvements with NAD+ precursors, but more clinical research needed.
Methods Used
Systematic review following PRISMA guidelines, searching two databases for studies published in last 5 years.
Main Finding
Potential benefits of NAD+ precursors (NR and NMN) for Alzheimer's disease, with 2 human trials showing improvements in biomarkers and cognition for NR, but no human trials for NMN.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No meta-analysis performed
- •Limited human trials (only 2) for NR, none for NMN
Surprising Findings
NMN, a popular supplement, has zero human trials for Alzheimer's – only 3 mouse studies.
Many people buy NMN based on preclinical hype, but this review highlights the complete lack of human evidence for Alzheimer's specifically.
Practical Takeaways
If you are considering NR or NMN supplements for Alzheimer's prevention or treatment, be aware that the human evidence is extremely limited (only 2 small NR trials, zero NMN human trials).
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
Human Systematic Review
Subject
Lower probability
on the GRADE evidence scale
Imagine you collected a bunch of reports from scientists who tested a new vitamin in mice and a couple of people. Some mice got better, and a few people showed improvements in memory tests. That’s a hint that the vitamin might help, but it’s not strong proof because we don’t know if the people taking it were compared to others who didn’t take it. So we can say ‘this vitamin might be linked to better memory,’ but we can’t say ‘this vitamin cures Alzheimer’s.’
Strengths
- Followed PRISMA guidelines for systematic review.
- Focused on a specific intervention (NAD+ precursors) and disease (Alzheimer's).
Weaknesses
- Full methodology not available - based on abstract only.
- Only searched two databases, potentially missing relevant studies.
- Included a mix of animal and human studies without separate analysis.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
Limited - based on abstract only, full methodology not available
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Systematic reviews and meta-analyses of cohort studies. They sit above a single cohort study but below a single randomized trial, because the underlying evidence is still observational.
This design cannot establish causation — the findings describe an association, not a cause. The systematic review includes mainly preclinical animal studies and only two human clinical trials that are not explicitly described as randomized controlled trials. Without randomization and control groups, causation cannot be established.
COI Unknown
Could not determine conflict of interest status
No conflict of interest or funding information is provided in the abstract, making it impossible to assess potential biases.
The abstract lacks any declarations regarding conflicts of interest, funding sources, or author affiliations. Further review of the full text is necessary to determine potential biases.